Mesenchymal Stem Cells Ameliorate Renal Inflammation in Adriamycin-induced Nephropathy

• Published in: Immune network Vol. 19; no. 5; pp. e36 - 10
• Main Authors: Kim, Hyung Sook, Lee, Jae Seob, Lee, Hong Kyung, Park, Eun Jae, Jeon, Hye Won, Kang, Yu Jeong, Lee, Tae Yong, Kim, Kyung Suk, Bae, Sang-Cheol, Park, Ji Hyun, Han, Sang-Bae
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Association of Immunologists 01.10.2019; 대한면역학회
• Subjects: Brief Communication; 면역학; Podocytes; Inflammation; Fibrosis; Mesenchymal stem cells
• ISSN: 1598-2629; 2092-6685
• DOI: 10.4110/in.2019.19.e36

Mesenchymal stem cells (MSCs) ameliorate the renal injury in Adriamycin (ADR)-induced nephropathy, but the mechanisms underlying their efficacy remain incompletely understood. In this study, we demonstrated that MSCs increased the survival, recovered body weight loss, and decreased proteinuria and serum creatinine levels in ADR-treated mice. MSCs also prevented podocyte damage and renal fibrosis by decreasing the expression of fibronectin, collagen 1α1, and α-smooth muscle actin. From a mechanistic perspective, MSCs inhibited renal inflammation by lowering the expression of CCL4, CCL7, CCL19, IFN-α/β, TGF-β, TNF-α, and chitinase 3-like 1. In summary, our data demonstrate that MSCs improve renal functions by inhibiting renal inflammation in ADR-induced nephropathy.